We're just as frustrated as you are with the stock price.

Our view of the global economy suggests several more quarters of low volume growth and continued price pressure, ... Lower raw material costs and more favorable currency comparison. combined with results from our productivity focus should all contribute to our ability to weather this cycle more favorably than in the past.

Suffice it to say that the price of the stock is an important part of the equation.

It's a great time to reinvest in our company. This action is yet another reflection of our commitment to enhance shareholder value.

We've just got to deliver what we've laid out here.

Accelerating the growth in life sciences is key to our strategy to becoming a faster-growing, more profitable, less cyclical company.